ClinicalTrials.gg
Not yet recruitingNCT07679919Updated Jul 1, 2026

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

A Phase 1 interventional study of LMY-922 in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Hairy Cell Leukemia, sponsored by Luminary Therapeutics. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Luminary Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 139 open to participants now, 254 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Planned enrollment
818th of 1,377
27 · median 35
Started
2026
with 24 others
Phase 1
528 of 1,599
47 open now
Primary completion
2029-04
later than 197 of 249 live
Registered
1,594th of 1,599
by date

Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 818th largest by planned enrollment of the 1,377 interventional ones that give a count, is one of 25 that started in 2026, is one of 528 in phase 1, reaches primary completion later than 197 of the 249 other live ones, and was the 1,594th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

139 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory hematologic malignancies, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against refractory hematologic malignancies using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.

Read the detailed description

LMY-922 is an allogeneic CAR-T cell therapy consisting of allogeneic cluster of differentiation 4 (CD4) positive and cluster of differentiation 8 (CD8) positive human T cells that are genetically engineered using the non-viral transposon system to express the BAFF-ligand CAR-T that target BAFF receptor family members to eliminate malignant B cells. BAFF receptor family includes B-cell activating factor receptor (BR3), B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). These receptors are present on refractory hematologic malignancies. The goal of LMY-922-002 phase 1 study is to find the recommended phase 2 dose of LMY-922 for treatment of patients with refractory hematologic malignancies.

03

Conditions studied

  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Hairy Cell Leukemia
  • Multiple Myeloma

Keywords

  • Lymphoma
  • B-cell
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Male or female 18-75 years of age. 2. Patient with:

a. NHL: confirmed B cell NHL (including but not limited to diffuse large B cell lymphoma (DLBCL), follicular lymphoma, MCL, marginal zone lymphoma (MZL)) i. after 2 or more , or ii. Have disease refractory to prior chemotherapy (defined as progressive disease or stable disease lasting ≤ 6 months, as best response to most recent chemotherapy regimen; or disease progression, or recurrence ≤ 12 months after prior stem cell transplantation (ASCT), and iii. per Lugano Revised Response Criteria for Malignant Lymphoma

or

b. CLL: histologically confirmed CLL i. Relapsed after 2 or more lines of therapy ii. Previous therapies prescribed must have included a Bruton's tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor, iii. Measurable disease and active disease: Active disease as defined by the iwCLL criteria, meeting at least one of the following criteria:

  1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia. Cutoff levels of \<10 g/dL or counts \<100 × 10\^9/L are generally regarded as indication for treatment.
  2. Massive (i.e., ≥6 cm below the left costal margin) or progressive or symptomatic splenomegaly.
  3. Massive nodes (i.e., ≥10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
  4. Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, spine, etc.).
  5. Disease-related symptoms as defined by any of the following:

    1. Unintentional weight loss ≥10% within the previous 6 months.
    2. Significant fatigue (i.e., (ECOG) performance scale 2 or worse; cannot work or unable to perform usual activities).
    3. Fevers ≥ 38.0°C for 2 or more weeks without evidence of infection.
    4. Night sweats for ≥1 month without evidence of infection.

or

c. HCL: histologically confirmed HCL i. Relapsed after at least one line of therapy, which must have included a purine nucleoside (eg. fludarabine, cladribine or pentostatin) and moxetumomab pasudotox.

ii. Need for treatment as evidenced by any one of the following: (ANC) \<1 × 10\^3/mcL, Hb \<10g/dL, platelet count \<100 × 10\^3/mcL, leukemia cell count >5 × 10\^3/mcL, symptomatic splenomegaly, or enlarging HCL mass >2 cm in short axis.

or

d. MM: histologically confirmed MM i. Relapsed or refractory after 3 or more lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.

ii. Measurable disease per IMWG uniform response criteria 3. Adequate organ function as defined by:

  1. more than or equal to 45 ml/min calculated by the Cockcroft - Gault formula
  2. Subjects must have adequate cardiac function as defined as ≥ 45% on the most recent echocardiogram and no arrhythmias, pericardial effusion, valvular, or ischemic heart disease.
  3. Adequate pulmonary function with pulse oximetry ≥ 92% on room air.
  4. Total \< 1.5× the institutional (\<2.5× if caused by the baseline cancer and in patients with Gilbert's syndrome).
  5. (ALT (Serum Glutamic-Pyruvic Transaminase (SGPT))) and Aspartate Aminotransferase (AST (Serum Glutamic-Oxaloacetic Transaminase (SGOT) \< 2.5× the institutional upper limit of normal.

    4. Subjects (or legal guardians) must have the ability to understand and the willingness to sign a written document.

    5. For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use a method with a failure rate of \< 1% per year during the treatment period and for at least 1 year after CAR-T cell infusion.

A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a state (\< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).

Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

The reliability of sexual abstinence should be evaluated in relation to the duration

of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

6. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for at least 1 year after CAR-T cell infusion. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 1 year after CAR-T cell infusion to avoid potential embryonal or fetal exposure.

The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

7. Body weight of at least 55kg for patients treated at dose level 3 (450 × million BAFF+ CAR cells) and at least 37kg for all other dose levels.

Exclusion criteria

Exclusion Criteria:

  1. Second active (i.e., currently requires antineoplastic therapy) non-B cell lineage , other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast).
  2. Renal failure requiring regular dialysis.
  3. Uncontrolled pulmonary disease or infection.
  4. Cardiovascular disorders including symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias, myocardial infarction or stroke (including , or other ischemic event) within 6 months prior to registration.
  5. Active infection requiring systemic treatment.
  6. seropositive with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 12 months of enrollment, or has not been on an established antiretroviral therapy (ART) for at least four weeks with an HIV viral load less than 400 copies/mL.
  7. Pregnant or breastfeeding women are excluded from this study (breastfeeding should be discontinued), because there is an unknown, but potential risk for adverse events in fetuses and nursing infants secondary to treatment of the mother with LMY-922 and lymphodepleting chemotherapy. Women of must have a negative serum pregnancy test.
  8. Serologic status reflecting active or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
  9. Patients with history of clinically relevant central nervous system (CNS) pathology such as uncontrolled epilepsy, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia, and Parkinson's disease.
  10. Subjects with uncontrolled intercurrent or psychiatric illness/social situations that would limit compliance with study requirements.
  11. Patients receiving a within 2 weeks prior to screening.
  12. Concurrent use of high dose systemic and/or therapies.

    1. Steroid dose must be weaned to ≤10 mg/day prednisone equivalent prior to CAR-T cell infusion.
    2. Immunosuppressive medications must be stopped at least 5 half-lives prior to CAR-T cell infusion.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Non-Hodgkin Lymphoma: LMY-922 Dose Level -1

    Dose Level -1 of 75 million BAFF+ CAR cells for the non-Hodgkin lymphoma group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Non-Hodgkin Lymphoma: LMY-922 Dose Level 1

    Dose Level 1 of 150 million BAFF+ CAR cells for the non-Hodgkin lymphoma group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Non-Hodgkin Lymphoma: LMY-922 Dose Level 2

    Dose Level 2 of 300 million BAFF+ CAR cells for the non-Hodgkin lymphoma group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Non-Hodgkin Lymphoma: LMY-922 Dose Level 3

    Dose Level 3 of 450 million BAFF+ CAR cells for the non-Hodgkin lymphoma group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Chronic Lymphocytic Leukemia / Hairy Cell Leukemia: LMY-922 Dose Level -1

    Dose Level -1 of 75 million BAFF+ CAR cells for the Chronic Lymphocytic Leukemia / Hairy Cell Leukemia group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Chronic Lymphocytic Leukemia / Hairy Cell Leukemia: LMY-922 Dose Level 1

    Dose Level 1 of 150 million BAFF+ CAR cells for the Chronic Lymphocytic Leukemia / Hairy Cell Leukemia group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Chronic Lymphocytic Leukemia / Hairy Cell Leukemia: LMY-922 Dose Level 2

    Dose Level 2 of 300 million BAFF+ CAR cells for the Chronic Lymphocytic Leukemia / Hairy Cell Leukemia group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Chronic Lymphocytic Leukemia / Hairy Cell Leukemia: LMY-922 Dose Level 3

    Dose Level 3 of 450 million BAFF+ CAR cells for the Chronic Lymphocytic Leukemia / Hairy Cell Leukemia group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Multiple Myeloma: LMY-922 Dose Level -1

    Dose Level -1 of 75 million BAFF+ CAR cells for the Multiple Myeloma group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Multiple Myeloma: LMY-922 Dose Level 1

    Dose Level 1 of 150 million BAFF+ CAR cells for the Multiple Myeloma group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Multiple Myeloma: LMY-922 Dose Level 2

    Dose Level 2 of 300 million BAFF+ CAR cells for the Multiple Myeloma group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

  • Experimental
    Multiple Myeloma: LMY-922 Dose Level 3

    Dose Level 3 of 450 million BAFF+ CAR cells for the Multiple Myeloma group of an open label, dose escalation study with up to four dose levels of LMY-922. The maximum tolerated dose of LMY-922 will be determined using dose-escalation 3+3 design.

    Biological: LMY-922

Interventions

  • BiologicalLMY-922

    Allogeneic CAR-T cell therapy expressing the BAFF-ligand

    Also known as: BAFF CAR-T Cells

06

What researchers measure

Primary outcomes

  1. To assess the safety profile of LMY-922 in patients with refractory hematologic malignancies.

    Incidence and severity of treatment-emergent adverse events

    Time frame: 12 Months

  2. To determine the Recommended Phase II Dose of LMY-922 in patients with refractory hematologic malignancies.

    Incidence of dose limiting toxicities (DLT)

    Time frame: 12 Months

Secondary outcomes

  1. Response rates for each malignancy

    NHL: per Lugano Revised Response Criteria for Malignant Lymphoma; CLL: per 2018 iwCLL criteria; HCL: per Consensus Guidelines for The Diagnosis and Management of Patients with Classic Hairy Cell Leukemia; MM: per IMWG uniform response criteria

    Time frame: 12 Months

  2. Progression free survival (PFS) for each malignancy

    Progression free survival

    Time frame: 12 Months

  3. Duration of response for each malignancy

    Duration of response

    Time frame: 12 Months

  4. Overall survival (OS) for each malignancy

    Overall survival

    Time frame: 12 Months

Other outcomes

  1. CAR-T cell expansion and persistence

    CAR-T cell expansion and persistence (described as maximum concentration (Cmax), time to maximum concentration (Tmax), area under the curve (AUC)s and other relevant pharmacokinetics (PK) parameters)

    Time frame: 12 Months

  2. Changes in serum concentration of cytokines

    Changes in serum concentration of cytokines and their correlation with toxicity and response.

    Time frame: 12 Months

  3. Expression of BR3 on tumor cells

    Expression of BR3 on tumor cells and the association with response

    Time frame: 12 Months

  4. Serum soluble BR3

    Serum soluble BR3 pre and post infusion and the correlation with clinical response

    Time frame: 12 Months

  5. Incidence of anti-LMY-922 antibodies

    Incidence of anti-LMY-922 antibodies

    Time frame: 12 Months

  6. Immune phenotype

    Immune phenotype (including B cell subsets) levels pre and post infusion.

    Time frame: 12 Months

  7. T cell proteomics

    T cell proteomics and correlation with toxicity and response.

    Time frame: 12 Months

  8. Expression of TACI on tumor cells

    Expression of TACI on tumor cells and the association with response.

    Time frame: 12 Months

  9. Expression of BCMA on tumor cells

    Expression of BCMA on tumor cells and the association with response.

    Time frame: 12 Months

  10. Serum soluble TACI

    Serum soluble TACI pre and post infusion and the correlation with clinical response

    Time frame: 12 Months

  11. Serum soluble BCMA

    Serum soluble BCMA pre and post infusion and the correlation with clinical response

    Time frame: 12 Months

  12. Immunoglobulin levels

    Immunoglobulin levels pre and post infusion.

    Time frame: 12 Months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Apr 2029, 31 months later.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 31 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 1, 2026
StartEst.
Sep 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07679919
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Sep 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Jul 1, 2026

Study contacts

Paolo F Caimi, MD
Contact
CAIMIP@ccf.org
216 445-4635

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion